Supernus Pharmaceuticals SUPN Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$38.55M-152% | $73.87M+5,513% | $1.32M-97.8% | $60.71M+13.6% | ||
| $91.56M+13.9% | $80.41M-5.2% | $84.86M-0.8% | $85.54M+162% | ||
| $33.05M+19.1% | $27.76M+3.7% | $26.76M+52.3% | $17.57M-1.9% | ||
| —— | $171.95M— | —— | $116.83M-11.0% | ||
| $1.34M+84.6% | $725K+23.5% | $587K— | —— | ||
| —— | -$189.87M— | —— | -$216.66M— | ||
| $9.13M-25.1% | $12.19M+103% | -$398.97M— | —— | ||
| —— | —— | -$18.07M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Supernus Pharmaceuticals's cash flow data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.